Patents Examined by Amanda L Aguirre
  • Heterocyclic compounds for use in electronic devices
    Patent number: 10957859
    Abstract: The present invention relates to heterocyclic compounds and to electronic devices, especially organic electroluminescent devices, comprising these compounds.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: March 23, 2021
    Assignee: Merck Patent GmbH
    Inventors: Anja Jatsch, Amir Hossain Parham, Thomas Eberle, Tobias Grossmann, Jonas Valentin Kroeber
  • Materials for electronic devices
    Patent number: 10957860
    Abstract: The application relates to a compound of a formula (I) which is suitable for use as functional material in electronic devices.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 23, 2021
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Elvira Montenegro, Frank Voges, Jonas Valentin Kroeber, Philipp Stoessel
  • System and method for solution phase gap peptide synthesis
    Patent number: 10947267
    Abstract: Disclosed is a system and method for Fmoc/tBu solution-phase peptide synthesis including the development of a new benzyl-type GAP protecting group, and related uses thereto. This novel GAP protecting group is utilized in place of a polymer support, facilitating C to N Fmoc peptide synthesis without chromatography, recrystallization, or polymer supports. The GAP group can be added and removed in high yield.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 16, 2021
    Assignee: Texas Tech University System
    Inventors: Guigen Li, Cole Seifert
  • Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 10947220
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 16, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex
    Patent number: 10946028
    Abstract: A DDS preparation of a platinum complex, which exhibits a superior antitumor effect required as a medicine and reduced side effects, that is, a clinically usable DDS preparation of a platinum complex, which is conjugated to a polymer carrier that is different from conventional carriers, is desired. Provided is a polymer conjugate of a platinum(II) complex, the polymer conjugate including: a block copolymer having a polyethylene glycol structural moiety and a polyaspartic acid moiety or a polyglutamic acid moiety; a sulfoxide derivative introduced into a side-chain carboxyl group of the block copolymer; and a platinum(II) complex coordinate-bonded to a sulfoxide group of the sulfoxide derivative.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: March 16, 2021
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Masaharu Nakamura, Tsuyoshi Fukuda, Ken Yamakawa, Takuya Kato
  • Materials for organic electroluminescent devices
    Patent number: 10944056
    Abstract: The present invention relates to spirobifluorene compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: March 9, 2021
    Assignee: Merck Patent GmbH
    Inventors: Elvira Montenegro, Amir H. Parham, Philipp Stoessel, Teresa Mujica-Fernaud, Frank Voges, Arne Buesing
  • Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
    Patent number: 10941118
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 9, 2021
    Assignee: Pfizer Inc.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Silicon-containing heterocyclic compound, and quencher
    Patent number: 10913855
    Abstract: Quenchers of the related art do not have a quenching ability high enough to sufficiently inhibit the emission of fluorescence from fluorescence compounds. Therefore, the present invention aims to provide a quencher which can sufficiently quench the fluorescence from fluorescent compounds including xanthene-based dyes. The present invention relates to a quencher formed of a compound represented by the following general formula (1), and the like.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: February 9, 2021
    Assignee: FUJIFILM Wako Pure Chemical Corporation
    Inventors: Katsufumi Suzuki, Tetsuji Murase, Shigeaki Imazeki
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10912771
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
    Type: Grant
    Filed: October 17, 2020
    Date of Patent: February 9, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Tetracycline compounds
    Patent number: 10913712
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: February 9, 2021
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Substituted benzamides useful as sodium channel blockers
    Patent number: 10899732
    Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 26, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Chien-an Chen, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Ivan William Hemeon, Steven McKerrall, Brian Salvatore Safina, Tao Sheng, Dan Sutherlin
  • Tetrazole based corrosion inhibitors
    Patent number: 10899721
    Abstract: Disclosed are corrosion inhibitor compounds and compositions useful for preventing or inhibiting corrosion of surfaces found in cooling water applications. In some embodiments, the surfaces may include mild steel, aluminum, brass, copper, galvanized steel, a copper alloy, admirality brass, or any combination thereof. Also disclosed are methods of using the compounds and compositions as corrosion inhibitors. In some embodiments, the corrosion inhibitor compounds and compositions are used in cooling water applications.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 26, 2021
    Assignee: ECOLAB USA INC.
    Inventors: Jothibasu Seetharaman, Edouard Andre Reny, Donald A. Johnson, Kailas B. Sawant, Vaideeswaran Sivaswamy
  • Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 10899748
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 26, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Substituted dihydropyrrolopyrazole derivative
    Patent number: 10894798
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: January 19, 2021
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Noriaki Iwase, Yasuhiro Aga, Shigeru Ushiyama, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Satoshi Umezaki, Masahiro Kojima, Kazuhiro Onuma, Yusuke Shiraishi, Makoto Okudo, Tomio Kimura
  • Bicyclic compounds as dual ATX/CA inhibitors
    Patent number: 10889588
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: January 12, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • Duplex stabilizing fluorescence quenchers for nucleic acid probes
    Patent number: 10890529
    Abstract: Diaryl-azo derivatives are efficient fluorescence quenchers as well as nucleic acid duplex-stabilizing agents and are useful in oligonucleotide conjugates and probes. The oligonucleotide-quencher conjugates may be used in detection methods for nucleic acid targets.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: January 12, 2021
    Assignee: ELITECHGROUP, INC.
    Inventors: Eugeny A. Lukhtanov, Noah Scarr
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10874648
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: December 29, 2020
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)
    Patent number: 10865181
    Abstract: The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: December 15, 2020
    Assignees: UNIVERSITY OF KANSAS, Oregon Health & Science University
    Inventors: Sudeshna Roy, Paolo Bernardi, Michael Forte, Frank Schoenen, Justina Sileikyte
  • Metabolically stable 5-HMF derivatives for the treatment of hypoxia
    Patent number: 10836729
    Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: November 17, 2020
    Assignee: King Abdulaziz University
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10815213
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 27, 2020
    Assignee: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt